Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients with Metastatic Breast Cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 0910-12
